ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / APLM / insiders
SPRO (40) INCR (46) OSTX (30) XBIT (32) ⌘ Pro Terminal →

Apollomics Inc. (Class A) (APLM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$20.84 +0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.83

Apollomics Inc. (Class A) (APLM) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $60.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APLM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APLM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Apollomics Inc. (Class A) (NASDAQ: APLM) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $20.84 (+0.73% 1D, market cap $60.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, APLM ranks #208 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APLM compare to SPRO and INCR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APLM carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPRO (Spero Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M) and INCR (Intercure Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $60.8M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APLM?
▼

For Apollomics Inc. (Class A) (APLM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #208 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.83 (-0.06%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk C+
Cash (12)Whales (7)SEC (13)Macro (14)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-1.3% Base Target
$30 Bull$21 Base$16 Bear
📬 FREE APLM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APLM)Realized 20D OHLCV Swing Band: ±10.1%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY APLM SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (25% of score)

FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 43.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
63
Grade C+$21.32+3.4% Next Q
Q2 (-2Q)
60
Grade C$22.05-9.8% Next Q
Q3 (-1Q)
58
Grade C$19.90+4.7% Next Q
Current
55
Grade D+$20.84-0.5% Hist 90D α
Trajectory: C+ (63) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the APLM Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, APLM faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.19) or 200D SMA ($18.95) invalidates the momentum regime and cuts Target Base ($20.56) toward Bear Floor ($16.04).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APLM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “APLM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 55%NO 45%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

APLM Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (APLM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on APLM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APLM)

  • ✓Walkthrough of APLM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
APLM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.25%🛡️ HOLDING TREND SUPPORT
2026-11-04O $20.69H $20.84L $20.69C $20.84VOL 4.9K
RES: $30.19SUP: $19.72SMA50: $23.19SMA200: $18.95
$29.37$24.90$20.43$15.96$11.49RES $30.19SUP $19.72$20.842026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APLM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APLM Butterfly Map → + Track APLM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on APLM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APLM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for APLM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APLM)

Health Care Rank #208 of 1015 ⚔️ SPRO vs APLM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APLM vs. SPRO, INCR, OSTX, XBIT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Apollomics Inc. (Class A) (APLM) ranks #208 by composite RQD confidence (55/100, grade D+) and #715 by equity capitalization ($60.4M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
APLM ACTIVE
Apollomics Inc. (Class A)
D+ 55/100 — — — +0.73% $60.4M Benchmark Subject
SPRO
Spero Therapeutics Inc.
D- 40/100 7.5x — 26.6% -1.89% $60.6M /spro-vs-aplm →
INCR
Intercure Ltd.
D 46/100 — — — +2.02% $60.8M /incr-vs-aplm →
OSTX
OS Therapies Incorporated
E 30/100 — — -35.0% -7.26% $59.8M /ostx-vs-aplm →
XBIT
XBiotech Inc.
E 32/100 — — -35.0% +2.13% $58.5M /xbit-vs-aplm →

2. APLM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Apollomics Inc. (Class A) (APLM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $60.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. APLM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APLM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Apollomics Inc. (Class A) (NASDAQ: APLM) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $20.84 (+0.73% 1D, market cap $60.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, APLM ranks #208 in composite RQD confidence.

How does APLM compare to SPRO and INCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APLM carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPRO (Spero Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M) and INCR (Intercure Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $60.8M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APLM?

For Apollomics Inc. (Class A) (APLM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #208 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APLM trading relative to its 50-day, 200-day, and 52-week technical levels?

APLM last traded at $20.84 (+0.73% on volume of 4,867 shares), positioning the stock -10.13% below its 50-day simple moving average ($23.19) and +9.97% above its 200-day simple moving average ($18.95). Across its 52-week range of $11.30 to $28.29, APLM sits at the 56.2% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($18.74 to $22.94).

Direct Sub-Reports: APLM RQD Cockpit APLM 12M Forecast APLM Earnings & Move APLM Dividends & DRIP APLM Insiders & 13F APLM Whale Options APLM Profit Sankey APLM News & Why
ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ SEC XBRL & RQD VERIFIED

APLM — Apollomics Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Apollomics Inc. (Class A) (APLM) earns a live Roarable RQD composite score of 55/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $20.84 (+0.73% 1D, market capitalization $60.4M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Apollomics Inc. (Class A) is a NASDAQ-listed issuer...1B. — describes its products, customers, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 55/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $11.30 – $28.29 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream dependencies, downstream customers, or sector correlation coefficients. Investors should note that the only sector context provided is the Health Care classification.

  • Key Question #1: Can APLM sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $28.29 52-week high?
  • Key Question #3: How sensitive is APLM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

APLM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Apollomics Inc. (Class A) (APLM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APLM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APLM Bull vs. Bear Conversation Board — What's Your Call at $20.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APLM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on APLM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $23.79 (+15.0%)
📌 Pinned Debate

Forensic Balance Sheet pillar scores 13 of 20 with Altman Z 2.5 and Piotroski F 6/9, the stronger side of the RQD profile.

Forensic Balance Sheet pillar scores 13 of 20 with Altman Z 2.5 and Piotroski F 6/9, the stronger side of the RQD profile.. When you look under the hood at APLM, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $28.29. My 12M target is $23.79.

RetailWhale_TX 🐂 BULL

Both sides have a point here — APLM's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $17.79 (-14.0%)
Spot @ $20.69

Fundamental Cash Engine pillar scores 12 of 20 with ROIC 0% and FCF yield 0%, with no reported financials to offset it.

Careful chasing APLM at $20.69. Fundamental Cash Engine pillar scores 12 of 20 with ROIC 0% and FCF yield 0%, with no reported financials to offset it.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $17.79 on multiple compression.

LIVE TAPE